Joel Cooper, M.D., has been a key figure in one
of the spectacular life-saving achievements in
the history of Alpha-1: lung transplantation.
It is common for someone with a chronic disease
such as COPD to also have other health concerns
affect their overall health. These additional
health concerns are called comorbidities (coe-more
bid i tees).
Pulmonary rehabilitation (pulmonary rehab) is a
program of exercise and education specifically
designed for people with COPD and other chronic lung
diseases. In pulmonary rehab, participants gain
strength, stamina, and flexibility, learn about their
lungs and how to stay as healthy and independent as
possible. They also find moral support and how to
cope with changes brought on by COPD.
When it comes to pregnancy and Alpha-1
Antitrypsin Deficiency (Alpha-1), Kyle
Hogarth, M.D., FCCP, says the most important
thing for a woman with Alpha-1 to know is
the genetics of her partner.
The year 2013 is the 50th anniversary of the
discovery of Alpha-1 Antitrypsin Deficiency
(Alpha-1) by the Swedish researchers Sten
Eriksson and Carl-Bertil Laurell. Alphas from around
the world recently took part in an International
Congress in Barcelona April 11-13 to mark the very
beginning of Alpha-1 history.
The specific treatment for lung disease is called
augmentation therapy. It is the use of alpha-1 protein
from the blood plasma of healthy human donors to
supplement or augment the low alpha-1 levels circulating
in the blood and lungs of Alphas diagnosed with
emphysema. The therapy is administered by a weekly
intravenous infusion and, until other therapies become
available, is considered ongoing and lifelong, according
to the Alpha-1 Foundation.
When the research fellow, Sten Eriksson, M.D.,
Ph.D., and his supervisor and mentor, Carl-Bertil
Laurell, M.D., Ph.D., reviewed the results and found
five patients out of 1500 who were missing the alpha-1
band of protein, they essentially discovered and named
the clinical entity, Alpha-1 Antitrypsin Deficiency